Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP).
A total of 33 evaluable patients with multiple myeloma refractory to alkylating agents were treated with the regimen vincristine, BCNU, doxorubicin, and prednisone (VBAP) at 3-week intervals in a single institution for a 5-yr period. An overall response rate of 21.2% was achieved (9% objective plus 12.2% improvement). Treatment was well tolerated. The overall median survival was 7.5 months. However, responding patients attained a median survival of 27.4 months vs. 5 months for similarly treated nonresponding subjects (P = 0.051). These results indicate that VBAP is an effective treatment for a proportion of patients with advanced refractory multiple myeloma.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D014750:Vincristine; D004317:Doxorubicin; D002330:Carmustine; D011241:Prednisone